Identification of potential targets for diallyl disulfide in human gastric cancer MGC-803 cells using proteomics approaches

BO SU1,3*, JIAN SU1,2,4*, HUI HE1,2*, YOUHUA WU1, HONG XIA1,2, XI ZENG1,2, WENXIANG DAI1, XIAOHONG AI1, HUI LING1,2, HAO JIANG1,2 and QI SU1,2

1Center for Gastric Cancer Research of Hunan Province, First Affiliated Hospital, 2Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, Cancer Research Institute, 3Key Laboratory for Pharmacoproteomics of Hunan Provincial University, Institute of Pharmacy and Pharmacology, 4Department of Pathology, Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China

Received November 27, 2014; Accepted February 26, 2015
DOI: 10.3892/or.2015.3859

Abstract. Diallyl disulfide (DADS) is characterized as an effective agent for the prevention and therapy of cancer, however, mechanisms regarding its anticancer effects are not fully clarified. In the present study, we compared the protein expression profile of gastric cancer MGC-803 cells subjected to DADS treatment with that of untreated control cells to explore potential molecules regulated by DADS. Using proteomic approaches, we identified 23 proteins showing statistically significant differences in expression, including 9 upregulated and 14 downregulated proteins. RT-PCR and western blot analysis confirmed that retinoid-related orphan nuclear receptor α (RORα) and nM23 were increased by DADS, whereas LIM kinase-1 (LIMK1), urokinase-type plasminogen activator receptor (uPAR) and cyclin-dependent kinase-1 (CDK1) were decreased. DADS treatment and knockdown of uPAR caused suppression of ERK/Fra-1 pathway, downregulation of urokinase-type plasminogen activator (uPA), matrix metalloproteinase-9 (MMP-9) and vimentin, and upregulation of tissue inhibitor of metalloproteinase-3 (TIMP-3) and E-cadherin, concomitant with inhibition of cell migration and invasion. Moreover, knockdown of uPAR potentiated the effects of DADS on MGC-803 cells. These data demonstrate that downregulation of uPAR may partially be responsible for DADS-induced inhibition of ERK/Fra-1 pathway, as well as cell migration and invasion. Thus, the discovery of DADS-induced differential expression proteins is conducive to reveal unknown mechanisms of DADS anti-gastric cancer.

Introduction

Gastric cancer, one of the most common human malignant tumors, accounts for the first leading cause of gastrointestinal cancer-related mortality worldwide (1), particularly in China (2). Chemotherapy has been shown to increase overall survival in patients with early gastric cancer after surgery over the years, yet survival in advanced and metastatic stages has not significantly improved (3).

Diallyl disulfide (DADS) is one of the organosulfur compounds that derive from Allium vegetables, such as garlic. Laboratory evidence has revealed that DADS exerts multiple antitumor effects on a variety of tumors by suppression of cell proliferation, angiogenesis or invasion, induction of apoptosis or differentiation (4,5), without gross toxicity based on the experiments in vivo (6,7). Therefore, as a putative anticancer agent to inhibit cancer cell growth and invasion, DADS has good prospects for clinical application of adjuvant therapy.

Many studies have shown that diverse molecular mechanisms are implicated in the suppressive effect of DADS on tumor growth (4,5). In particular, a few studies suggest that DADS inhibits cancer cell invasion through reducing the expression and activities of matrix metalloproteinases (MMPs) (8,9). However, the underlying mechanisms are still largely unknown. Thus, potential molecules regulated by DADS remain to be explored to elucidate its inhibitory effect on tumor growth, particularly metastasis.

We have previously demonstrated that DADS induces G2/M phase cell cycle arrest in gastric cancer cell lines via ATR/Chk1/Cdc25/Cyclin B1 signaling pathway, accompanied with an increase in Chk1 phosphorylation (10,11) and a decrease in Cdc25C expression through activation of p38 (12). In addition, DADS induced cell differentiation by downregulating ERK signaling pathway (13). Our recent study showed that DADS suppresses gastric cancer growth and induces apoptosis by upregulation of miRNA-200b and miRNA-22 (14).

To further explore potential molecular targets affected by DADS in gastric cancer, we screened and obtained
some proteins through proteomics research approaches, which showed significantly differential expression between DADS-treated and untreated gastric cancer cells in the present study. The expression changes of retinoid-related orphan nuclear receptor α (RORα), M23, cyclin-dependent kinase-1 (CDK1), urokinase-type plasminogen activator receptor (uPAR) and LIM kinase-1 (LIMK1) were verified in subsequent experiments. We further explored the effects of DADS on the ERK/Fra-1 pathway, as well as the invasion and epithelial-mesenchymal transition (EMT)-associated protein expression. We proposed that DADS-induced suppression of migration and invasion of gastric cancer cells may be in part, due to downregulation of the uPAR and the ERK/Fra-1 pathway.

Materials and methods

Reagents and antibodies. DADS (purity 80%, the remaining 20% being diallyl trisulfide and diallyl sulfide), purchased from Fluka Co. (Milwaukee, WI, USA), was dissolved in TWEEN-80 and stored at -20°C after a 100-fold dilution with saline. The primary antibodies for LIMK1 (ab81046), uPAR (ab89932), Fra-1 (ab117951), E-cadherin (ab40772), MMP-9 (ab38898), TIMP-3 (ab39184) and vimentin (ab92547) were purchased from Abcam (Abcam, Cambridge, UK). The antibody primary antibodies for RORα (sc-6062), nM23-H1 (sc-343), CDK1 (sc-54), ERK1/2 (sc-135900), p-ERK1/2 (sc-292838) and β-actin (sc-47778) and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell culture and cell line establishment. Human gastric cancer cell line MGC-803 was obtained from the Cancer Research Institute, Xiangya Medical College, Center South University in China. The cells were cultured in RPMI-1640 medium (Gibco, Life Technologies, Vienna, Austria), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies, USA), 100 µg/ml streptomycin, and 100 U/ml penicillin G (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO2 and 95% air at 37°C. The samples were mixed and incubated on ice for 30 min and then centrifuged at 15,000 rpm for 30 min. The supernatant was transferred to the fresh tube and stored in -80°C until use. The total protein concentration was measured according to the Bradford protein assay method with bovine serum albumin as standard.

Preparation of protein samples for two-dimensional electrophoresis (2-DE). DADS-treated and -untreated cells were harvested and lysed in lysis buffer containing 8 M urea, 4% CHAPS, 40 mM Tris, 1% DDT, 0.5% immobilized pH gradient (IPG) buffer (all from Amersham Biosciences) and protease inhibitor mixture (Roche Molecular Biochemicals). The samples were mixed and incubated on ice for 30 min and then centrifuged at 15,000 rpm for 30 min. The supernatant was transferred to a fresh tube and stored in -80°C until use. The total protein concentration was measured according to the Bradford protein assay method with bovine serum albumin as standard.

2-DE. 2-DE was carried out to separate proteins from DADS-treated and -untreated cells of three independent experiments. Protein (200 µg) was taken from each extract then dissolved in a 320 µl rehydration solution (8 M urea, 4% CHAPS, 65 mM DDT, 0.5% IPG buffer and a trace of bromophenol blue) and placed at room temperature for 40 min, then loaded to 18 cm IPG strips containing a wide-range of pH gradient 3-10 (Amersham Biosciences). Rehydration and isoelectric focusing (IEF) were performed at 20°C for 12 h at 50 V, followed by 50 µA/IPG strip, 500 V for 1 h, 1,000 V for 1 h, 8,000 V for 4 h 30 min using an IPGphor (Amersham Biosciences). Following IEF, the IPG strips were equilibrated with equilibration buffer (6 M urea, 2% sodium dodecyl sulfate, 50 mM Tris-HCl, pH 8.8, 30% glycerol and 1% DTT) for 15 min, and then they were put in the same solution, with 2.5% iodoacetamide replacing DTT, for an additional 15 min with gentle shaking. The equilibrated strips were transferred to the top of 12.5% SDS PAGE gels and embedded in 1% low-melting agarose containing a trace of bromophenol blue. Electrophoresis was carried out using Ettan DALTsix system (GE Healthcare) at 25 w/gel for 30 min, and then 17 w/gel until the bromophenol blue dye reached the bottom of the gel. Then, the gels were fixed (40% ethanol, 10% acetic acid) and silver stained using the PlusOne silver staining kit (Amersham Biosciences) as described in the instructions of the manufacturer.

Gel imaging and spot analysis. Gels were scanned using the Molecular Imager Gel Doc XR System and analyzed using the PDQuest system (both from Bio-Rad), according to the protocols provided by the manufacturer. Spot intensities were quantified by calculation of spot volume after normalization of the image using the total spot volume normalization method. Protein spots showing at least a 2.0-fold difference in abundance between control and treatment were considered as differentially expressed. The selected protein spots
that were statistically analyzed by the Student's t-test with P<0.05 were considered to indicate a statistically significant result.

**Mass spectrometry analysis.** The excised spots of interest were destained and digested as previously described (15). Briefly, protein spots were destained with 15 mM K$_3$[Fe(CN)$_6$] and 50 mM Na$_2$S$_2$O$_3$. Gel pieces were incubated in the digestion solution with 20 µg/ml trypsin (Amresco) for 10-12 h at 37°C. The tryptic peptide mixture was mixed with α-cyano-4-hydroxycinnamic acid matrix solution (Sigma-Aldrich, St. Louis, MO, USA). One microliter of the mixture was analyzed by the Voyager System DE-STR 4307 matrix-assisted laser desorption/ionization time of flight mass spectrometer (MALDI-TOF-MS) (Applied Biosystems, Foster City, CA, USA). Protein identification was performed by matching the peptide mass fingerprints against the Swiss-Prot or the NCBInr database with the MS-Fit search program (http://prospector.ucsf.edu/). Molecular weight (Mr) and isoelectric point (pI) of the identified proteins were subsequently compared with the experimental values obtained from the 2-DE image analysis.

**Reverse transcription-polymerase chain reaction (RT-PCR).** Total RNA was extracted from the cells using TRIzol reagent (Invitrogen). Reverse transcription was carried out using the GeneAmp PCR kit (Promega, Madison, WI, USA). Primer sequences were as follows: RORα F, 5'-GTC AGC AGC TTC TAC CTG GAC-3' and R, 5'-GTG TTG TTC TGA GAG AGG AGT TTT TAA TC-3'; β-actin F, 5'-TCT ACA ATG AGC TGC GTG TAA GC-3' and R, 5'-TCT ACA ATG AGC TGC GTG TAA GC-3'; β-actin F, 5'-AGG GCA GAC CAC ATT GCT TT-3' and R, 5'-GCT GGG GGG AAG CAA CCT AG-3'; nM23 F, 5'-AGG GCA GAC CAC ATT GCT TT-3' and R, 5'-GTG TTG TTC TGA GAG TTT TCG TGG AT-3'. For CDK1 F, 5'-AGT CAG TCT TCA GCA GCA-3' and R, 5'-CCA CCT ATT CCC GAA GCC GTT AC-3'; 5'-CCA CCT ATT CCC GAA GCC GTT AC-3'; β-actin F, 5'-ACA CTG TCG TCA CCT ACG AGG GG-3' and R, 5'-ATG ATG AGG TGG AAG GTA GTC TTC CCG TGG AT-3'. For unPAR F, 5'-TCA CCT ATT CCC GAA GCC GTT AC-3' and R, 5'-AGA GTG AGC GTT GGT GAG TGC C-3'; β-actin F, 5'-CCC ACA CTG TGC CCA TCT AC-3' and R, 5'-GCC GCA GTC GTC ATA CTC CT-3'. For CDK1 F, 5'-AGT CAG TCT TCA GGA TGT GCT-3' and R, 5'-TGA CAT GAT GGT CTA GGC TT-3'; β-actin F, 5'-TGG CAT CCA GCA AAC TAC CT-3' and R, 5'-TCA CCT TCA CCC TTC GAG TT-3'. The PCR products were analyzed on a 2% agarose gel containing ethidium bromide. The densitometric quantitation of the products was determined using Lab-work analysis software. The ratio of target gene to β-actin was calculated to obtain the relative fold-changes in gene expression. A DL1000 DNA ladder and a 100 bp DNA ladder were used as the markers (Takara, Dalian, China).

**Western blot analysis.** For the total protein extraction, the cells were lysed on ice for 30 min in 0.1 ml lysis buffer [10 mmol/l Tris-HCl (pH 7.6), 100 mmol/l NaCl, 1 mmol/l EDTA (pH 8.0), 100 µg/ml PMSF and 1 µg/ml aprotinin]. The cell lysates were centrifuged at 12,000 rpm for 10 min, and the protein contents were determined by the BCA protein assay kit (Pierce, Rockford, IL, USA). The protein extracts were resolved on 12% SDS-polyacrylamide gels for electrophoresis and transferred onto the PVDF membranes. The membranes were incubated with 5% skim milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 2 h at room temperature and then they were incubated with the primary antibody at 4°C overnight. After being washed with TBS-T, the membranes were then incubated with the HRP-conjugated secondary antibody (1:1,000-2,000). The membranes were developed by an enhanced chemiluminescence plus kit (Amersham Biosciences, Buckinghamshire, UK) and bands were visualized on X-ray film (Kodak). The target protein amounts were normalized towards β-actin quantity using densitometry, and relative fold-changes in protein levels were calculated.

**Migration assays.** Cell migration was evaluated using the scratch wound assay as previously described (16). Briefly, the cells were cultured to 90% confluence in a 6-well plate and washed with serum-free RPMI-1640 medium. The cell monolayers were wounded with a 10-µl plastic pipette tip. After, the cells were untreated or treated with 30 mg/l DADS, the wound areas were photographed using an inverted microscope. The distance that the cells migrated from the wound edge was measured and a mean value of five independent microscopic fields was calculated. The experiments were repeated three times. Migration rates were expressed as ratios between treated vs. control group values or between 24 vs. 0 h group values.

**Invasion assays.** Invasion assays were carried out using Transwell™ (Corning, Corning, NY, USA) as previously described (16). Matrigel (25 µg) (Becton-Dickinson, Bedford, MA, USA) dilution was added to the upslope of porous filters (pore size, 8-µm) and allowed to gel at 37°C overnight. After the coated filters were rehydrated with 100 µl medium, 1x10³ cells in 200 µl serum-free medium supplemented with 0.2% bovine serum albumin were seeded into the upper part of each chamber, whereas the lower compartments were filled with 500 µl of culture medium. The cells were treated or untreated with 30 mg/l DADS. The invaded cells on the lower membrane surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The experiments were repeated three times. Invasiveness was determined by counting an average number of cells from four microscopic fields/well, and invasion rates were expressed as ratios between treated vs. control group values, or between 24 vs. 0 h group values.

**Statistical analyses.** All the results are presented as mean ± SD or SE of three independent experiments. The Student's t-test and the one-way ANOVA were used to identify statistical significance. A two-sided P<0.05 was considered to indicate a statistically significant result.

**Results**

**DADS inhibits MGC-803 cell migration and invasion.** We first treated cells with 20, 30 and 40 mg/l DADS for 24 h, and examined the effects of DADS on migration and invasion of the gastric cancer MGC-803 cell line. As shown in Fig. 1A and B, DADS reduced migration and invasion rates of the cells in a concentration-dependent manner. These data indicate that treatment with DADS significantly inhibited migration and
invasion activities of MGC-803 cells. Our previous studies have demonstrated that 30 mg/l DADS is able to cause the arrest of the G/M phase of the cell cycle and the growth inhibition of the gastric cancer cells (10) based on IC_{50} values for
DADS (17). Thus, incubation with 30 mg/l DADS was used in the subsequent experiments.

Identification of differential expression proteins by 2-DE and MS. To analyze the differential expression proteins induced by DADS in gastric cancer MGC-803 cells, the cells were treated with 30 mg/l DADS for 24 h. The proteins from DADS-treated and untreated cells were resolved by 2-DE respectively, and the gels were stained with silver to visualize the protein spots in the 2-DE gels. Two representative 2-DE maps from DADS-treated and untreated group are shown in Fig. 2A and B, respectively. By comparing the ratio of each spot in the gels, 291 protein spots that had consistent differences (≥2-fold) between DADS-treated group and the untreated group in triplicate experiments were considered as differentially expressed. Among them, 23 selected differential protein spots were excised from the stained gels, subjected to trypsin digestion. Twenty-three differentially expressed proteins were identified based on MALDI-TOF-MS and database query with MS-Fit (Table I). These protein spots are marked with arrows in Fig. 2A and B.

Verification of DADS-induced differential expression genes in MGC-803 cells. Among the identified proteins, RORα, nM23, LIMK1, uPAR and CDK1 displayed significantly differential expression in DADS-treated cells compared with the untreated cells. A representative comparison of the five proteins is shown in Fig. 2C. These five proteins were subjected to further validation. RT-PCR and western blot analysis were performed to explore the expression pattern of these five genes after the MGC-803 cells were exposed to 30 mg/l DADS for various times. As shown in Fig. 3A, the mRNA levels of RORα and nM23 increased in a time-dependent manner. Whereas, LIMK1, uPAR and CDK1 mRNA levels decreased in a time-dependent manner. Accordingly, similar changes in the protein levels were also observed in the MGC-803 cells upon DADS treatment (Fig. 3B). Therefore, changes in the gene expression induced by DADS were confirmed at the transcriptional and translational levels.

<table>
<thead>
<tr>
<th>Spot no.</th>
<th>Accession no.</th>
<th>Protein name</th>
<th>Mr (Da)/pI</th>
<th>Matched peptides</th>
<th>Sequence coverage (%)</th>
<th>Expression alteration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Q30136</td>
<td>HLA-DRB1 protein</td>
<td>24901.0/7.22</td>
<td>8</td>
<td>46</td>
<td>Upregulated</td>
</tr>
<tr>
<td>2</td>
<td>O60522</td>
<td>Antigen NY-CO-45</td>
<td>85665.9/4.46</td>
<td>12</td>
<td>21</td>
<td>Downregulated</td>
</tr>
<tr>
<td>3</td>
<td>Q03405</td>
<td>Urokinase-type plasminogen activator receptor</td>
<td>31263.6/6.01</td>
<td>8</td>
<td>26</td>
<td>Downregulated</td>
</tr>
<tr>
<td>4</td>
<td>P15531</td>
<td>Metastasis inhibition factor nm23</td>
<td>20411.6/7.06</td>
<td>10</td>
<td>51</td>
<td>Upregulated</td>
</tr>
<tr>
<td>5</td>
<td>O00429</td>
<td>Dynamin-1-like protein</td>
<td>81877.6/6.37</td>
<td>19</td>
<td>25</td>
<td>Downregulated</td>
</tr>
<tr>
<td>6</td>
<td>O60602</td>
<td>Toll-like receptor 5/Toll/interleukin-1 receptor-like protein 3</td>
<td>97692.0/6.21</td>
<td>10</td>
<td>17</td>
<td>Downregulated</td>
</tr>
<tr>
<td>7</td>
<td>Q92782</td>
<td>Zinc finger protein neuro-d4</td>
<td>39875.8/6.28</td>
<td>7</td>
<td>28</td>
<td>Downregulated</td>
</tr>
<tr>
<td>8</td>
<td>O08499</td>
<td>Phosphodiesterase 4D</td>
<td>76466.9/4.86</td>
<td>8</td>
<td>15</td>
<td>Downregulated</td>
</tr>
<tr>
<td>9</td>
<td>P98088</td>
<td>Mucin-5AC/gastric mucin</td>
<td>91762.7/6.85</td>
<td>35</td>
<td>40</td>
<td>Upregulated</td>
</tr>
<tr>
<td>10</td>
<td>Q86XL3</td>
<td>Ankyrin repeat and LEM domain-containing protein 2</td>
<td>87454.5/6.37</td>
<td>21</td>
<td>29</td>
<td>Downregulated</td>
</tr>
<tr>
<td>11</td>
<td>P98170</td>
<td>X-linked inhibitor of apoptosis protein</td>
<td>56701.3/6.22</td>
<td>7</td>
<td>26</td>
<td>Downregulated</td>
</tr>
<tr>
<td>12</td>
<td>P20062</td>
<td>Transcobalamin-2</td>
<td>47535.3/6.52</td>
<td>11</td>
<td>25</td>
<td>Downregulated</td>
</tr>
<tr>
<td>13</td>
<td>P33981</td>
<td>Dual specificity protein kinase TTK</td>
<td>95279.9/8.66</td>
<td>26</td>
<td>31</td>
<td>Upregulated</td>
</tr>
<tr>
<td>14</td>
<td>P40926</td>
<td>Malate dehydrogenase</td>
<td>35531.5/8.92</td>
<td>8</td>
<td>35</td>
<td>Upregulated</td>
</tr>
<tr>
<td>15</td>
<td>P52597</td>
<td>Heterogeneous nuclear ribonucleoprotein F</td>
<td>45672.1/5.38</td>
<td>6</td>
<td>23</td>
<td>Downregulated</td>
</tr>
<tr>
<td>16</td>
<td>P53667</td>
<td>LIM kinase-1</td>
<td>83045.8/6.05</td>
<td>7</td>
<td>14</td>
<td>Downregulated</td>
</tr>
<tr>
<td>17</td>
<td>Q14934</td>
<td>Nuclear factor of activated T-cells</td>
<td>95473.3/5.29</td>
<td>11</td>
<td>19</td>
<td>Downregulated</td>
</tr>
<tr>
<td>18</td>
<td>Q99676</td>
<td>Zinc finger protein 184</td>
<td>83269.5/8.50</td>
<td>12</td>
<td>26</td>
<td>Upregulated</td>
</tr>
<tr>
<td>19</td>
<td>P35398</td>
<td>Nuclear receptor RORα</td>
<td>60336.2/5.97</td>
<td>10</td>
<td>16</td>
<td>Upregulated</td>
</tr>
<tr>
<td>20</td>
<td>P01850</td>
<td>T-cell receptor β-1 chain C region</td>
<td>34440.2/6.23</td>
<td>5</td>
<td>31</td>
<td>Upregulated</td>
</tr>
<tr>
<td>21</td>
<td>P78536</td>
<td>TNF-α-converting enzyme</td>
<td>92961.5/5.59</td>
<td>9</td>
<td>14</td>
<td>Downregulated</td>
</tr>
<tr>
<td>22</td>
<td>Q9UNN8</td>
<td>Endothelial protein C receptor</td>
<td>26641.6/6.70</td>
<td>5</td>
<td>33</td>
<td>Upregulated</td>
</tr>
<tr>
<td>23</td>
<td>P06493</td>
<td>Cyclin-dependent kinase 1/CDC2</td>
<td>27502.9/6.54</td>
<td>5</td>
<td>11</td>
<td>Downregulated</td>
</tr>
</tbody>
</table>

*aSwiss-Prot accession number; bspot intensity ≥2-fold increased or decreased in DADS-treated group in comparison with untreated group.

DADS, diallyl disulfide; RORα, nuclear receptor α.
translational levels, which were consistent with the results from the comparative proteomics research.

**DADS inhibits the ERK/Fra-1 pathway through decreasing uPAR expression in MGC-803 cells.** uPAR activates diverse cell signaling pathways, including the ERK/Fra-1 pathway. We hypothesized that the decreased expression of uPAR induced by DADS may cause inhibition of the ERK/Fra-1 pathway. To test this hypothesis, we first constructed several stable uPAR-interfering MGC-803 cell lines using microRNA (miR), and then chose miR3, which showed the most knockdown efficacy, for the following experiments (Fig. 4A). Then, we determined the levels of phosphorylated ERK1/2 in DADS-treated and uPAR-interfering cells. As anticipated, knockdown of uPAR resulted in decreased levels of p-ERK1/2 (Fig. 4B). The levels of Fra-1 protein were also downregulated by DADS and knockdown
Figure 4. DADS blocks the ERK/Fra-1 pathway through decreasing uPAR expression in MGC803 cells. (A) The MGC803 cells were transfected with the uPAR-microRNA (miR1, miR2 and miR3) or the empty vectors, and RT-PCR and western blotting were performed to detect the mRNA and protein expression levels of the uPAR. (B) p-ERK, total ERK and Fra-1 protein levels were determined by western blotting in uPAR-microRNA transfected and DADS-treated cells. β-actin was used as a loading control. The relative fold-changes in the protein level compared with the empty vector groups were calculated. *P<0.05 vs. control or the empty vector group. DADS, diallyl disulfide; uPAR, urokinase-type plasminogen activator receptor.

Figure 5. Downregulation of uPAR by DADS affects invasion and EMT-associated protein expression in MGC-803 cells. The cells transfected with uPAR-miR or the empty vector were treated or untreated with 30 mg/l DADS for 24 h. The expression of uPAR, (A) uPA and MMP-9, (B) vimentin and TIMP-3, (C) and E-cadherin proteins were determined by western blot analysis. β-actin was used as a loading control. The relative fold-changes in the protein level compared with the empty vector groups (controls) were calculated. *P<0.05 vs. control, #P<0.05 vs. control, the uPAR-miR or the DADS group. uPAR, urokinase-type plasminogen activator receptor; DADS, diallyl disulfide; EMT, epithelial-mesenchymal transition; uPA, urokinase-type plasminogen activator; MMP-9, matrix metalloproteinase-9; TIMP-3, tissue inhibitor of metalloproteinase-3.
of uPAR (Fig. 4B). These data suggest that downregulation of uPAR by DADS inhibited ERK1/2 activities and Fra-1 expression, leading to blockage of ERK/Fra-1 pathway.

**Downregulation of uPAR by DADS affects invasion and EMT-associated protein expression in MGC-803 cells.** Activation of the ERK/Fra-1 pathway is involved in positively regulating cancer cell invasion and EMT-related genes, such as uPA and MMP-9. Fig. 5A and B showed that uPA (urokinase-type plasminogen activator) and MMP-9 expression were attenuated by DADS, accompanied by downregulation of uPAR. Moreover, similar results were observed in the uPAR-interfering cells. Moreover, DADS upregulated TIMP-3 (tissue inhibitor of metalloproteinase-3) expression (Fig. 5C). Next, we examined the expression levels of vimentin and E-cadherin, which were taken as markers of EMT. Both DADS and knockdown of uPAR decreased the vimentin and increased the E-cadherin expression (Fig. 5B and C). Moreover, knockdown of uPAR is able to augment these effects induced by DADS (Fig. 5A-C).
Downregulation of uPAR potentiates inhibitory effects of DADS on MGC-803 cell migration and invasion. To test whether DADS-induced downregulation of uPAR is responsible for inhibition of MGC-803 cell migration and invasion, we performed the scratch wound and invasion assays. The results showed that the migration rates of the cells after uPAR knockdown were obviously reduced in contrast to the vector group, as well as that of the DADS-treated cells in contrast to the control group (Fig. 6A). Moreover, both DADS-treated and uPAR knockdown cells exhibited a significant decrease in the invasion rates (Fig. 6B). In addition, stronger inhibitory effects on cell migration and invasion were found in the uPAR-interfering cells exposed to DADS for 24 h (Fig. 6A and B).

**Discussion**

In the present study, we identified differentially expressed proteins induced by DADS in gastric cancer cells using the comparative proteomics technique. Among them, RORα, nM23, LIMK1, uPAR and CDK1 attracted our attention since dysregulation of their expression and function is closely correlated with tumorigenesis and progression, particularly invasion and metastasis. The effects of DADS on these gene expression have not yet been reported in the gastric cancer cells.

RORα is a member of the orphan nuclear factor family that regulates gene expression by binding to ROR response elements. Its decreased expression is shown in cancers, suggesting that RORα inactivation may be one mechanism underlying tumorigenesis (18). Activation of RORα suppresses the expression of Wnt/β-catenin target genes, resulting in inhibition of proliferation and migration of colon cancer cells (19). RORα inhibits breast cancer cell invasion by transactivation of SEMA3F, a suppressive microenvironmental factor (20). Thus, RORα has been proposed to act as a tumor suppressor. In gastric cancer, methylation silence of the RORα gene may be one reason for its inactivation (21). Our previous studies demonstrated that DADS could upregulate p21 expression through augmenting histone acetylation (22), we speculate that this epigenetic mechanism may be implicated in DADS-induced RORα expression in MGC-803 cells, and upregulation of RORα by DADS may contribute to its bioactivity against gastric cancer cell growth and invasion.

Nm23 is characterized as a specific metastasis suppressor ascribed to its multiple activities involving regulation of tumor metastatic process. The decreased Nm23 expression facilitates tumor cell motility and invasion, while its overexpression in aggressive cancer cells suppresses their metastatic capacity (23). Nm23 silencing promotes invadopodia formation, activation of pro-invasive signaling pathways and upregulation of MMPs (24). Whereas, re-expression of Nm23 attenuates metastatic ability of cancer cells by altering the expression of metastasis-related genes (25,26). Therefore, effort has been made to develop agents to recover Nm23 function in cancer cells. For an example, lycopene reduces experimental tumor metastasis in vivo via increasing Nm23 protein expression (27). It has been reported that the decreased Nm23 protein level was observed in lymph node and liver metastases in contrast to primary lesions of gastric cancer (28). In the present study, our data indicated that DADS upregulates Nm23 expression in gastric cancer cells. It suggests that restoration of nm23 bioactivity may be a mechanism underlying DADS anti-invasion effect on gastric cancer cells.

LIM kinases (LIMK1 and LIMK2) are the common downstream effectors of Rho-ROCK, Rac-PAK and Cdc42-MRCK pathways that regulate rearrangements of actin cytoskeleton. Functional dysregulation of LIMKs, due to their overexpression and overactivation, in particular LIMK1 (29,30), promotes the formation and maturation of matrix-degrading invadopodia, which facilitate cancer cell invasion (31). Whereas, knockdown of LIMK1 expression blocks invadopodia formation, and reduces MMP-9 expression and matrix protein degradation, decreasing the invasive potential of cancer cells (31). Our previous study demonstrated that the suppressive effects of DADS on colon cancer cell motility and invasiveness are associated with attenuating Rac1-Rock1/Pak1-LIMK1 signaling pathway (32). Thus, LIMK1 may be a candidate target for DADS against gastric cancer cell invasion.

uPAR is a glycolipid-anchored cell surface receptor. Its elevated expression indicates poor prognosis in many human tumors, including gastric cancer (33). In addition to mediating the degradation of extracellular matrix by its interaction with uPA to activate plasminogen and MMPs, uPAR interacts with co-receptors to activate intracellular signaling pathways (34). Furthermore, overactivation of uPAR-dependent signaling pathways fosters EMT and invasion, and these cellular changes are blocked by silencing uPAR (35) or uPA (36) expression. Since various signaling pathways are involved in inducing uPAR expression, which in turn stimulates gastric cancer cell invasiveness, uPAR has been considered as a potential therapeutic target (37). It has been demonstrated that ERK activation promotes the expression of the AP-1 family transcription factor Fra-1, which is essential for cell invasion through modulating invasion-associated gene expression, such as uPA and MMP-9 (38). The present study showed that DADS reduced uPAR expression in the MGC-803 cells, suggesting that a decrease in uPAR protein may lead to suppression of its downstream effectors of ERK/Fra-1, resulting in inhibition of cell migration and invasion. To testify this assumption, we examined effects of DADS on ERK/Fra-1 pathway and its target gene expression in MGC-803 cells. Our data showed that DADS decreased phosphorylation of ERK1/2 and Fra-1 expression, concomitant with the decreased expression of uPA and MMP-9. Additionally, DADS increased the expression of TIMP-3, which inhibits the catalytic activity of MMPs to maintain extracellular matrix (ECM) homeostasis. These changes resulting from DADS-induced downregulation of uPAR were supported by the similar results that were observed in uPAR knockdown cells. Notably, we found that DADS downregulates vimentin and upregulates E-cadherin expression, and these results were consistent with the observations in the uPAR knockdown cells. Recent researches indicated that overactivation of ERK/Fra-1 pathway induces EMT (39,40), and Fra-1 is involved in regulation of the expression of vimentin (41) and E-cadherin (42). Based on these findings, we proposed that DADS may inhibit EMT in gastric cancer cells, which may partially account for its inhibitory effect on MGC-803 cell invasion. Notably, DADS is able to exert more potent effects on uPAR knockdown cells. We speculate that DADS-induced invasion inhibition may involve other mechanisms that remain
to be revealed except for downregualtion of uPAR, such as inhibition of LIMK1 and upregulation of RORα and Nm23.

CDK1 plays a critical role in promoting the transition of the G2/M phase of the cell cycle through the formation of a complex between CDK1 and cyclin B1 or cyclin A. Its functional dysregulation results in tumor cell unlimited proliferation. Inhibition of CDK1 expression and activity is an effective approach to suppress tumor growth and sensitize cancer cells to apoptosis (43,44). We previously reported that the decrease of CDK1 expression and its interaction with Mei1 (an anti-apoptotic factor) are involved in the DADS-induced G2/M phase arrest in human leukemia HL-60 cells (45). In the present study, we revealed that DADS reduces CDK1 expression in gastric cancer MGC-803 cells. It suggests that the inhibitory effect of DADS on CDK1 may contribute to the treatment of gastric cancer, since gastric tumor tissues show higher CDK1 expression and activity than non-neoplastic mucosa (46).

In summary, we revealed that DADS is able to increase RORα and nM23 expression and decrease LIMK1, uPAR and CDK1 expression. DADS-induced downregulation of uPAR is able to partially account for inhibition of the ERK/Fra-1 pathway, and migration and invasion of gastric MGC-803 cells. These findings are valuable for revealing potential targets for DADS, but further studies are required to demonstrate its anti-gastric cancer mechanisms.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (nos. 81374013, 31201027, 31100935, 81102854, 31000629 and 81100375), the Key Project Foundation of the Science and Technology program of Hunan Province of China (no. 04SK004), the Patency Foundation of Innovation Platform of Hunan Provincial University of China (no. 09K074), the Key Project of Scientific Research Foundation of Hunan Province Education Department of China (no. 09A077), the Key Hunan Provincial Natural Science Foundation of China (no. 07JJ3033) and the Construct Program of the Key Discipline in Hunan Province of China (no. 2011-76).

References


